The genes encoding most glycolytic enzymes are under dominant transcriptional control by PI3K/AKT and thus hyperglycemia is one of the most common side-effects with PI3K pathway inhibitors [7]. This evidence concerns the gene PIK3CA and Hyperglycemia.